
ZBH Stock Forecast & Price Target
ZBH Analyst Ratings
Bulls say
Zimmer Biomet Holdings is a leading company in the orthopedic reconstructive market due to its extensive product portfolio and global market share. Despite challenges in its Foot & Ankle division and slower organic growth, the company continues to invest in new product development, which has improved its product vitality index. The company also has a strong balance sheet and has shown a commitment to returning capital to shareholders through share buybacks. While the current growth outlook may limit the stock's valuation, the potential for upside from improving end markets and successful integration of recent acquisitions make Zimmer Biomet a strong investment opportunity for long-term investors.
Bears say
Zimmer Biomet Holdings is facing challenges in meeting revenue and earnings expectations due to weaker organic growth and changes in the salesforce. Despite potential in new products and markets, the company's financial results have been average, and its stock is expected to trade at a P/E multiple of 10x in 2027. In addition, there are potential risks from slower markets, integration challenges, and competition in the orthopedic industry.
This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.
ZBH Analyst Forecast & Price Prediction
Start investing in ZBH
Order type
Buy in
Order amount
Est. shares
0 shares